Organon & Co. (OGN) Financials

$13.36 +0.03 (+0.19%)

As of 01:55 PM Eastern

Annual Income Statements for Organon & Co.

This table shows Organon & Co.'s income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	3,218	2,160	1,351	917	1,023	864	187
Consolidated Net Income / (Loss)	3,218	2,160	1,351	917	1,023	864	187
Net Income / (Loss) Continuing Operations	3,306	2,256	1,351	917	1,023	864	187
Total Pre-Tax Income	3,696	2,752	1,529	1,122	673	807	425
Total Operating Income	3,762	2,787	1,791	1,570	1,257	1,374	824
Total Gross Profit	5,503	4,413	3,905	3,880	3,748	3,715	3,313
Total Revenue	7,777	6,532	6,304	6,174	6,263	6,403	6,216
Operating Revenue	7,777	6,532	6,304	6,174	6,263	6,403	6,216
Total Cost of Revenue	2,274	2,119	2,399	2,294	2,515	2,688	2,903
Operating Cost of Revenue	2,274	2,119	2,399	2,294	2,515	2,688	2,903
Total Operating Expenses	1,741	1,626	2,114	2,310	2,491	2,341	2,489
Selling, General & Admin Expense	1,443	1,356	1,668	1,704	1,893	1,760	1,721
Research & Development Expense	220	210	443	578	536	550	372
Impairment Charge	-	-	-	-	0.00	0.00	301
Restructuring Charge	78	60	3.00	28	62	31	95
Total Other Income / (Expense), net	-66	-35	-262	-448	-584	-567	-399
Interest Expense	-	0.00	258	422	527	520	504
Other Income / (Expense), net	-66	-35	-4.00	-26	-57	-47	105
Income Tax Expense	390	496	178	205	-350	-57	238
Basic Earnings per Share	$12.69	$8.52	$5.33	$3.61	$4.01	$3.36	$0.72
Weighted Average Basic Shares Outstanding	253.52M	253.52M	253.54M	254.08M	255.24M	257.05M	259.50M
Diluted Earnings per Share	$12.69	$8.52	$5.31	$3.59	$3.99	$3.33	$0.72
Weighted Average Diluted Shares Outstanding	253.52M	253.52M	254.19M	255.17M	256.27M	259.15M	260.76M
Weighted Average Basic & Diluted Shares Outstanding	-	-	253.64M	254.38M	255.64M	257.95M	260.32M
Cash Dividends to Common per Share	-	-	$0.56	$1.12	$1.12	$1.12	$0.34

This table shows Organon & Co.'s income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	58	546	201	195	359	109	87	145	160	-205	146
Consolidated Net Income / (Loss)	58	546	201	195	359	109	87	145	160	-205	146
Net Income / (Loss) Continuing Operations	58	546	201	195	359	109	87	145	160	-205	146
Total Pre-Tax Income	80	104	236	235	207	129	101	229	243	-148	213
Total Operating Income	232	254	376	371	339	288	233	324	358	-91	235
Total Gross Profit	907	915	957	939	923	896	841	874	857	741	783
Total Revenue	1,519	1,598	1,622	1,607	1,582	1,592	1,513	1,594	1,602	1,507	1,460
Operating Revenue	1,519	-	1,622	1,607	1,582	-	1,513	1,594	1,602	1,507	1,460
Total Cost of Revenue	612	683	665	668	659	696	672	720	745	766	677
Operating Cost of Revenue	612	683	665	668	659	696	672	720	745	766	677
Total Operating Expenses	675	661	581	568	584	608	608	550	499	832	548
Selling, General & Admin Expense	538	469	431	437	422	470	420	453	415	433	424
Research & Development Expense	137	134	127	131	162	130	102	95	84	91	93
Restructuring Charge	0.00	58	23	0.00	0.00	8.00	86	2.00	0.00	7.00	31
Total Other Income / (Expense), net	-152	-150	-140	-136	-132	-159	-132	-95	-115	-57	-22
Interest Expense	134	143	131	131	126	153	124	131	128	109	111
Other Income / (Expense), net	-18	-7.00	-9.00	-5.00	-6.00	-6.00	-8.00	36	13	52	89
Income Tax Expense	22	-442	35	40	-152	20	14	84	83	57	67
Basic Earnings per Share	$0.23	$2.13	$0.78	$0.76	$1.39	$0.43	$0.34	$0.56	$0.61	($0.79)	$0.56
Weighted Average Basic Shares Outstanding	255.59M	255.24M	255.70M	257.29M	257.50M	257.05M	257.86M	259.94M	259.98M	259.50M	260.37M
Diluted Earnings per Share	$0.23	$2.12	$0.78	$0.75	$1.38	$0.42	$0.33	$0.56	$0.61	($0.78)	$0.55
Weighted Average Diluted Shares Outstanding	256.35M	256.27M	258.36M	258.60M	259.76M	259.15M	261.00M	260.16M	260.65M	260.76M	262.90M
Weighted Average Basic & Diluted Shares Outstanding	255.61M	255.64M	257.17M	257.47M	257.54M	257.95M	259.96M	259.97M	259.98M	260.32M	262.60M
Cash Dividends to Common per Share	$0.28	-	$0.28	$0.28	$0.28	-	$0.28	$0.02	$0.02	-	$0.02

This table details how cash moves in and out of Organon & Co.'s business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	75	-246	667	-31	-13	-18	-101
Net Cash From Operating Activities	3,020	2,284	2,160	858	799	939	700
Net Cash From Continuing Operating Activities	3,020	2,284	2,160	858	799	939	700
Net Income / (Loss) Continuing Operations	3,306	2,256	1,351	917	1,023	864	187
Consolidated Net Income / (Loss)	-	-	1,351	917	1,023	864	187
Depreciation Expense	49	56	92	96	120	132	156
Amortization Expense	284	86	103	116	116	145	205
Non-Cash Adjustments To Reconcile Net Income	41	35	200	199	180	225	386
Changes in Operating Assets and Liabilities, net	-660	-149	414	-470	-640	-427	-234
Net Cash From Investing Activities	-88	-250	-481	-420	-260	-513	-390
Net Cash From Continuing Investing Activities	-88	-250	-481	-420	-260	-513	-390
Purchase of Property, Plant & Equipment	-92	-255	-192	-196	-251	-175	-162
Acquisitions	0.00	0.00	-296	-231	-10	-342	-229
Sale of Property, Plant & Equipment	4.00	5.00	7.00	7.00	1.00	4.00	1.00
Net Cash From Financing Activities	-2,932	-2,022	-977	-433	-569	-368	-561
Net Cash From Continuing Financing Activities	-2,932	-2,022	-977	-433	-569	-368	-561
Repayment of Debt	0.00	0.00	-1,742	-108	-338	-1,235	-1,513
Payment of Dividends	0.00	0.00	-145	-290	-294	-297	-88
Issuance of Debt	0.00	1,512	9,470	0.00	80	1,186	1,055
Other Financing Activities, net	-2,932	-3,534	-8,560	-35	-17	-22	-15
Effect of Exchange Rate Changes	31	-	23	-36	17	-76	150

This table details how cash moves in and out of Organon & Co.'s business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	88	279	-118	129	59	-88	-128	52	73	-98	542
Net Cash From Operating Activities	261	397	76	332	141	390	75	220	264	141	225
Net Cash From Continuing Operating Activities	261	397	76	332	141	390	75	220	264	141	225
Net Income / (Loss) Continuing Operations	58	546	201	195	359	109	87	145	160	-205	146
Consolidated Net Income / (Loss)	58	546	201	195	359	109	87	145	160	-205	146
Depreciation Expense	32	32	32	32	34	34	34	36	40	46	39
Amortization Expense	29	28	33	34	35	43	50	53	52	50	47
Non-Cash Adjustments To Reconcile Net Income	44	55	28	50	76	71	35	25	31	295	-47
Changes in Operating Assets and Liabilities, net	98	-264	-218	21	-363	133	-131	-39	-19	-45	40
Net Cash From Investing Activities	-55	-81	-96	-46	-75	-296	-172	-38	-115	-65	386
Net Cash From Continuing Investing Activities	-55	-81	-96	-46	-75	-296	-172	-38	-115	-65	386
Purchase of Property, Plant & Equipment	-55	-79	-46	-32	-42	-55	-32	-39	-46	-45	-37
Acquisitions	-	-2.00	-50	-15	-34	-243	-140	-	-69	-20	-10
Divestitures	-	-	-	-	-	-	0.00	-	-	-	433
Other Investing Activities, net	-	-	-	-	-	-	-	-	-	-	0.00
Net Cash From Financing Activities	-78	-77	-74	-134	-78	-82	-75	-223	-76	-187	-38
Net Cash From Continuing Financing Activities	-78	-77	-74	-134	-78	-82	-75	-223	-76	-187	-38
Repayment of Debt	-2.00	-2.00	-2.00	-1,077	-2.00	-154	-93	-541	-372	-507	-32
Payment of Dividends	-74	-73	-70	-79	-74	-74	-71	-10	-3.00	-4.00	-5.00
Issuance of Debt	-	-	0.00	-	-	150	90	340	300	325	0.00
Other Financing Activities, net	-2.00	-2.00	-2.00	-14	-2.00	-4.00	-1.00	-12	-1.00	-1.00	-1.00
Other Net Changes in Cash	-	-	-	-	-	-	-	-	-	-	-31

This table presents Organon & Co.'s assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	10,109	10,681	10,955	12,058	13,101	12,867
Total Current Assets	3,567	3,760	3,931	4,508	4,348	4,352
Cash & Equivalents	12	737	706	693	675	574
Accounts Receivable	1,038	1,382	1,475	1,744	1,358	1,331
Inventories, net	913	915	1,003	1,315	1,321	1,406
Other Current Assets	930	726	747	756	994	1,033
Other Current Nonoperating Assets	674	-	-	-	0.00	8.00
Plant, Property, & Equipment, net	984	973	1,018	1,183	1,168	1,303
Total Noncurrent Assets	5,558	5,948	6,006	6,367	7,585	7,212
Goodwill	4,603	4,603	4,603	4,603	4,680	4,153
Intangible Assets	503	651	649	533	1,414	1,130
Other Noncurrent Operating Assets	361	-	754	-	1,491	1,539
Other Noncurrent Nonoperating Assets	91	-	-	-	0.00	390
Total Liabilities & Shareholders' Equity	10,109	10,681	10,955	12,058	13,101	12,867
Total Liabilities	4,623	12,189	11,847	12,128	12,629	12,115
Total Current Liabilities	2,673	2,597	2,512	2,918	2,718	2,390
Short-Term Debt	0.00	9.00	8.00	9.00	20	16
Accounts Payable	1,598	1,382	1,132	1,314	1,153	952
Accrued Expenses	659	1,021	1,188	1,389	1,411	1,335
Current Deferred & Payable Income Tax Liabilities	288	185	184	206	134	85
Other Current Nonoperating Liabilities	128	-	-	-	0.00	2.00
Total Noncurrent Liabilities	1,950	9,592	9,335	9,210	9,911	9,725
Long-Term Debt	0.00	9,125	8,905	8,751	8,860	8,628
Noncurrent Deferred & Payable Income Tax Liabilities	128	4.00	19	47	74	57
Other Noncurrent Operating Liabilities	1,739	463	411	412	977	1,008
Other Noncurrent Nonoperating Liabilities	83	-	-	-	0.00	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5,486	-1,508	-892	-70	472	752
Total Preferred & Common Equity	5,486	-1,508	-892	-70	472	752
Total Common Equity	5,486	-1,508	-892	-70	472	752
Common Stock	0.00	3.00	3.00	28	111	170
Retained Earnings	0.00	-998	-331	443	1,010	1,109
Accumulated Other Comprehensive Income / (Loss)	-622	-513	-564	-541	-649	-527

This table presents Organon & Co.'s assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	10,437	10,763	10,979	11,012	11,891	12,154	12,752	13,156	13,500	13,552	12,996
Total Current Assets	3,592	3,780	3,958	4,050	4,196	4,509	4,756	4,371	4,618	4,700	4,932
Cash & Equivalents	499	459	326	414	575	704	763	547	599	672	1,116
Accounts Receivable	1,440	1,445	1,672	1,648	1,547	1,617	1,685	1,457	1,484	1,484	1,384
Inventories, net	879	1,121	1,199	1,186	1,263	1,287	1,383	1,362	1,454	1,488	1,373
Other Current Assets	774	755	761	802	811	901	925	1,005	1,081	1,056	1,059
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	-	-	0.00
Plant, Property, & Equipment, net	906	1,055	1,110	1,096	1,180	1,162	1,204	1,197	1,266	1,290	1,279
Total Noncurrent Assets	5,939	5,928	5,911	5,866	6,515	6,483	6,792	7,588	7,616	7,562	6,785
Goodwill	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,680	4,680	4,680	4,153
Intangible Assets	670	621	592	561	718	684	763	1,417	1,362	1,340	1,099
Noncurrent Deferred & Refundable Income Taxes	-	704	716	702	1,194	1,196	1,426	1,491	-	-	1,533
Other Noncurrent Nonoperating Assets	-	-	-	-	-	-	-	-	-	-	0.00
Total Liabilities & Shareholders' Equity	10,437	10,763	10,979	11,012	11,891	12,154	12,752	13,156	13,500	13,552	12,996
Total Liabilities	11,503	11,500	11,534	11,601	11,843	12,010	12,259	12,614	12,767	12,646	12,093
Total Current Liabilities	2,328	2,346	2,387	2,491	2,545	2,755	2,790	2,615	2,796	2,679	2,500
Short-Term Debt	8.00	8.00	8.00	8.00	9.00	9.00	10	20	115	45	16
Accounts Payable	1,028	996	1,115	1,067	955	1,243	1,092	1,006	1,067	1,074	983
Accrued Expenses	1,075	1,150	1,101	1,255	1,385	1,302	1,458	1,413	1,420	1,444	1,424
Current Deferred & Payable Income Tax Liabilities	217	192	163	161	196	201	230	176	194	116	77
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	-	0.00
Total Noncurrent Liabilities	9,175	9,154	9,147	9,110	9,298	9,255	9,469	9,999	9,971	9,967	9,593
Long-Term Debt	8,691	8,703	8,722	8,646	8,705	8,647	8,739	8,936	8,781	8,783	8,553
Noncurrent Deferred & Payable Income Tax Liabilities	43	30	32	43	44	60	56	69	69	62	56
Other Noncurrent Operating Liabilities	441	421	393	421	549	548	674	994	1,121	1,122	984
Other Noncurrent Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	-	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-1,066	-737	-555	-589	48	144	493	542	733	906	903
Total Preferred & Common Equity	-1,066	-737	-555	-589	48	144	493	542	733	906	903
Total Common Equity	-1,066	-737	-555	-589	48	144	493	542	733	906	903
Common Stock	3.00	3.00	3.00	3.00	52	66	89	133	142	162	189
Retained Earnings	-383	-206	-25	-16	573	690	975	1,026	1,163	1,318	1,253
Accumulated Other Comprehensive Income / (Loss)	-686	-534	-533	-576	-577	-612	-571	-617	-572	-574	-539

This table displays calculated financial ratios and metrics derived from Organon & Co.'s official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	-16.01%	-3.49%	-2.06%	1.44%	2.24%	-2.92%
EBITDA Growth	0.00%	-28.17%	-31.51%	-10.65%	-18.07%	11.99%	-19.58%
EBIT Growth	0.00%	-25.54%	-35.07%	-12.76%	-22.07%	10.95%	-29.99%
NOPAT Growth	0.00%	-32.11%	-30.73%	-18.92%	48.91%	-23.01%	-75.35%
Net Income Growth	0.00%	-32.88%	-37.45%	-32.12%	11.56%	-15.54%	-78.36%
EPS Growth	0.00%	-32.86%	-37.68%	-32.39%	11.14%	-16.54%	-78.38%
Operating Cash Flow Growth	0.00%	-24.37%	-5.43%	-60.28%	-6.88%	17.52%	-25.45%
Free Cash Flow Firm Growth	0.00%	0.00%	85.33%	321.77%	43.35%	-35.62%	-26.48%
Invested Capital Growth	0.00%	0.00%	40.02%	6.18%	9.32%	8.50%	-2.52%
Revenue Q/Q Growth	0.00%	0.00%	-0.16%	-1.88%	1.84%	-0.09%	-1.35%
EBITDA Q/Q Growth	0.00%	0.00%	-7.69%	-5.24%	1.75%	4.30%	-18.97%
EBIT Q/Q Growth	0.00%	0.00%	-9.70%	-5.34%	1.42%	3.85%	-25.68%
NOPAT Q/Q Growth	0.00%	0.00%	-5.25%	-2.30%	77.11%	-33.27%	-57.77%
Net Income Q/Q Growth	0.00%	0.00%	-10.94%	-9.30%	74.87%	-33.59%	-62.67%
EPS Q/Q Growth	0.00%	0.00%	-11.06%	-9.11%	74.24%	-33.80%	-62.50%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-16.83%	34.48%	19.43%	-0.74%	-26.24%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.67%	118.71%	-42.53%	111.05%
Invested Capital Q/Q Growth	0.00%	0.00%	3.25%	2.54%	4.52%	2.34%	-6.67%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	70.76%	67.56%	61.94%	62.84%	59.84%	58.02%	53.30%
EBITDA Margin	51.81%	44.31%	31.44%	28.68%	23.17%	25.38%	20.75%
Operating Margin	48.37%	42.67%	28.41%	25.43%	20.07%	21.46%	13.26%
EBIT Margin	47.52%	42.13%	28.35%	25.25%	19.40%	21.05%	14.95%
Profit (Net Income) Margin	41.38%	33.07%	21.43%	14.85%	16.33%	13.49%	3.01%
Tax Burden Percent	87.07%	78.49%	88.36%	81.73%	152.01%	107.06%	44.00%
Interest Burden Percent	100.00%	100.00%	85.56%	71.97%	55.39%	59.87%	45.75%
Effective Tax Rate	10.55%	18.02%	11.64%	18.27%	-52.01%	-7.06%	56.00%
Return on Invested Capital (ROIC)	0.00%	92.87%	26.80%	18.07%	24.96%	17.64%	4.23%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	136.93%	20.89%	13.66%	14.05%	10.18%	2.03%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-14.13%	41.12%	-94.48%	-237.64%	412.21%	26.32%
Return on Equity (ROE)	0.00%	78.75%	67.92%	-76.42%	-212.68%	429.85%	30.56%
Cash Return on Invested Capital (CROIC)	0.00%	-107.13%	-6.55%	12.07%	16.05%	9.49%	6.79%
Operating Return on Assets (OROA)	0.00%	27.22%	17.19%	14.41%	10.56%	10.72%	7.16%
Return on Assets (ROA)	0.00%	21.37%	13.00%	8.48%	8.89%	6.87%	1.44%
Return on Common Equity (ROCE)	0.00%	78.75%	67.92%	-76.42%	-212.68%	429.85%	30.56%
Return on Equity Simple (ROE_SIMPLE)	0.00%	39.37%	-89.59%	-102.80%	-1,461.43%	183.05%	0.00%
Net Operating Profit after Tax (NOPAT)	3,365	2,285	1,582	1,283	1,911	1,471	363
NOPAT Margin	43.27%	34.98%	25.10%	20.78%	30.51%	22.97%	5.83%
Net Nonoperating Expense Percent (NNEP)	0.00%	-44.06%	5.91%	4.41%	10.91%	7.46%	2.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	16.00%	21.99%	15.73%	3.86%
Cost of Revenue to Revenue	29.24%	32.44%	38.06%	37.16%	40.16%	41.98%	46.70%
SG&A Expenses to Revenue	18.55%	20.76%	26.46%	27.60%	30.23%	27.49%	27.69%
R&D to Revenue	2.83%	3.21%	7.03%	9.36%	8.56%	8.59%	5.98%
Operating Expenses to Revenue	22.39%	24.89%	33.53%	37.42%	39.77%	36.56%	40.04%
Earnings before Interest and Taxes (EBIT)	3,696	2,752	1,787	1,559	1,215	1,348	929
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4,029	2,894	1,982	1,771	1,451	1,625	1,290
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	7.99	2.47
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	1.05	1.00	0.54	0.59	0.30
Price to Earnings (P/E)	0.00	0.00	4.91	6.74	3.33	4.37	9.94
Dividend Yield	0.00%	0.00%	2.14%	6.92%	8.40%	7.64%	4.75%
Earnings Yield	0.00%	0.00%	20.37%	14.84%	30.03%	22.90%	10.06%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.18	1.97	1.43	1.38	1.17
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	2.38	2.33	1.83	1.87	1.60
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	7.58	8.12	7.91	7.37	7.70
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	8.41	9.23	9.44	8.89	10.69
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	9.50	11.21	6.01	8.14	27.39
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	6.96	16.77	14.36	12.76	14.19
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	16.78	9.34	15.14	17.07
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	-6.06	-9.99	-125.14	18.81	11.49
Long-Term Debt to Equity	0.00	0.00	-6.05	-9.98	-125.01	18.77	11.47
Financial Leverage	0.00	-0.10	1.97	-6.92	-16.92	40.48	13.00
Leverage Ratio	0.00	1.84	5.23	-9.02	-23.92	62.58	21.22
Compound Leverage Factor	0.00	1.84	4.47	-6.49	-13.25	37.47	9.71
Debt to Total Capital	0.00%	0.00%	119.77%	111.12%	100.81%	94.95%	92.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.12%	0.10%	0.10%	0.21%	0.17%
Long-Term Debt to Total Capital	0.00%	0.00%	119.66%	111.02%	100.70%	94.74%	91.83%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	-19.77%	-11.12%	-0.81%	5.05%	8.00%
Debt to EBITDA	0.00	0.00	4.61	5.03	6.04	5.46	6.70
Net Debt to EBITDA	0.00	0.00	4.24	4.63	5.56	5.05	6.26
Long-Term Debt to EBITDA	0.00	0.00	4.60	5.03	6.03	5.45	6.69
Debt to NOPAT	0.00	0.00	5.77	6.95	4.58	6.04	23.84
Net Debt to NOPAT	0.00	0.00	5.31	6.40	4.22	5.58	22.26
Long-Term Debt to NOPAT	0.00	0.00	5.77	6.94	4.58	6.02	23.80
Altman Z-Score	0.00	0.00	1.47	1.46	1.23	1.26	1.12
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	1.33	1.45	1.56	1.54	1.60	1.82
Quick Ratio	0.00	0.39	0.82	0.87	0.84	0.75	0.80
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-2,635	-387	857	1,229	791	582
Operating Cash Flow to CapEx	3,431.82%	913.60%	1,167.57%	453.97%	319.60%	549.12%	434.78%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-1.50	1.96	2.27	1.46	1.15
Operating Cash Flow to Interest Expense	0.00	0.00	8.37	1.96	1.47	1.74	1.39
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	7.66	1.53	1.01	1.42	1.07
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.65	0.61	0.57	0.54	0.51	0.48
Accounts Receivable Turnover	0.00	6.29	5.21	4.32	3.89	4.13	4.62
Inventory Turnover	0.00	2.32	2.62	2.39	2.17	2.04	2.13
Fixed Asset Turnover	0.00	6.64	6.44	6.20	5.69	5.45	5.03
Accounts Payable Turnover	0.00	1.33	1.61	1.83	2.06	2.18	2.76
Days Sales Outstanding (DSO)	0.00	58.00	70.06	84.45	93.80	88.41	78.95
Days Inventory Outstanding (DIO)	0.00	157.27	139.06	152.59	168.20	178.97	171.44
Days Payable Outstanding (DPO)	0.00	275.26	226.70	200.00	177.49	167.50	132.33
Cash Conversion Cycle (CCC)	0.00	-59.99	-17.58	37.04	84.51	99.89	118.05
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	4,920	6,889	7,315	7,997	8,677	8,458
Invested Capital Turnover	0.00	2.66	1.07	0.87	0.82	0.77	0.73
Increase / (Decrease) in Invested Capital	0.00	4,920	1,969	426	682	680	-219
Enterprise Value (EV)	0.00	0.00	15,029	14,385	11,474	11,978	9,929
Market Capitalization	0.00	0.00	6,632	6,178	3,407	3,773	1,859
Book Value per Share	$0.00	$21.64	($5.95)	($3.51)	($0.27)	$1.83	$2.89
Tangible Book Value per Share	$0.00	$1.50	($26.67)	($24.15)	($20.37)	($21.83)	($17.43)
Total Capital	0.00	5,486	7,626	8,021	8,690	9,352	9,396
Total Debt	0.00	0.00	9,134	8,913	8,760	8,880	8,644
Total Long-Term Debt	0.00	0.00	9,125	8,905	8,751	8,860	8,628
Net Debt	0.00	-12	8,397	8,207	8,067	8,205	8,070
Capital Expenditures (CapEx)	88	250	185	189	250	171	161
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	882	435	721	906	975	1,404
Debt-free Net Working Capital (DFNWC)	0.00	894	1,172	1,427	1,599	1,650	1,978
Net Working Capital (NWC)	0.00	894	1,163	1,419	1,590	1,630	1,962
Net Nonoperating Expense (NNE)	147	125	231	366	888	607	176
Net Nonoperating Obligations (NNO)	0.00	-566	8,397	8,207	8,067	8,205	7,706
Total Depreciation and Amortization (D&A)	333	142	195	212	236	277	361
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	13.50%	6.90%	11.68%	14.47%	15.23%	22.59%
Debt-free Net Working Capital to Revenue	0.00%	13.69%	18.59%	23.11%	25.53%	25.77%	31.82%
Net Working Capital to Revenue	0.00%	13.69%	18.45%	22.98%	25.39%	25.46%	31.56%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$5.33	$3.61	$4.01	$3.36	$0.72
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	253.54M	254.08M	255.24M	257.05M	259.50M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$5.31	$3.59	$3.99	$3.33	$0.72
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	254.19M	255.17M	256.27M	259.15M	260.76M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	253.64M	254.38M	255.64M	257.95M	260.32M
Normalized Net Operating Profit after Tax (NOPAT)	3,435	2,334	1,585	1,306	923	984	854
Normalized NOPAT Margin	44.17%	35.73%	25.15%	21.15%	14.74%	15.36%	13.74%
Pre Tax Income Margin	47.52%	42.13%	24.25%	18.17%	10.75%	12.60%	6.84%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	6.93	3.57	2.24	2.49	1.84
NOPAT to Interest Expense	0.00	0.00	6.13	2.94	3.53	2.72	0.72
EBIT Less CapEx to Interest Expense	0.00	0.00	6.21	3.14	1.78	2.18	1.52
NOPAT Less CapEx to Interest Expense	0.00	0.00	5.42	2.50	3.06	2.40	0.40
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	10.73%	31.62%	28.74%	34.38%	47.06%
Augmented Payout Ratio	0.00%	0.00%	10.73%	31.62%	28.74%	34.38%	47.06%

This table displays calculated financial ratios and metrics derived from Organon & Co.'s official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	260,315,650.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	260,315,650.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.56
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.17%	7.61%	5.46%	-0.06%	4.15%	-0.38%	-6.72%	-0.81%	1.26%	-5.34%	-3.50%
EBITDA Growth	-38.48%	3.37%	1.89%	-2.92%	46.18%	16.94%	-25.69%	3.94%	15.17%	-83.14%	32.69%
EBIT Growth	-45.13%	0.82%	0.00%	-5.43%	55.61%	14.17%	-35.42%	-1.64%	11.41%	-114.94%	44.00%
NOPAT Growth	-47.50%	415.24%	11.30%	-16.94%	249.54%	-81.75%	-37.33%	-33.36%	-59.91%	-126.18%	-19.74%
Net Income Growth	-74.45%	405.56%	13.56%	-19.42%	518.97%	-80.04%	-56.72%	-25.64%	-55.43%	-288.07%	67.82%
EPS Growth	-74.16%	404.76%	13.04%	-21.05%	500.00%	-80.19%	-57.69%	-25.33%	-55.80%	-285.71%	66.67%
Operating Cash Flow Growth	-17.67%	48.69%	-33.33%	1,129.63%	-45.98%	-1.76%	-1.32%	-33.73%	87.23%	-63.85%	200.00%
Free Cash Flow Firm Growth	-146.29%	489.68%	-355.17%	122.76%	31.17%	-167.02%	-60.14%	-1,297.76%	-44.66%	135.57%	234.22%
Invested Capital Growth	7.25%	9.32%	8.94%	3.15%	10.82%	8.50%	9.33%	11.54%	6.88%	-2.52%	-6.65%
Revenue Q/Q Growth	-5.53%	5.20%	1.50%	-0.92%	-1.56%	0.63%	-4.96%	5.35%	0.50%	-5.93%	-3.12%
EBITDA Q/Q Growth	-38.20%	11.64%	47.95%	0.00%	-6.94%	-10.70%	-10.59%	39.88%	3.12%	-87.69%	619.30%
EBIT Q/Q Growth	-44.70%	15.42%	58.19%	-0.27%	-9.02%	-15.32%	-15.96%	51.90%	3.06%	-110.51%	930.77%
NOPAT Q/Q Growth	-54.62%	692.81%	-74.48%	-3.87%	90.98%	-58.61%	-17.52%	2.22%	14.90%	-127.02%	352.87%
Net Income Q/Q Growth	-76.03%	841.38%	-63.19%	-2.99%	84.10%	-69.64%	-20.18%	66.67%	10.34%	-228.13%	171.22%
EPS Q/Q Growth	-75.79%	821.74%	-63.21%	-3.85%	84.00%	-69.57%	-21.43%	69.70%	8.93%	-227.87%	170.51%
Operating Cash Flow Q/Q Growth	866.67%	52.11%	-80.86%	336.84%	-57.53%	176.60%	-80.77%	193.33%	20.00%	-46.59%	59.57%
Free Cash Flow Firm Q/Q Growth	-30.45%	286.78%	-161.42%	117.30%	-494.52%	-81.88%	-29.00%	-29.39%	52.35%	144.72%	386.85%
Invested Capital Q/Q Growth	-2.52%	4.52%	2.38%	-1.11%	4.73%	2.34%	3.16%	0.88%	0.35%	-6.67%	-1.21%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.71%	57.26%	59.00%	58.43%	58.34%	56.28%	55.58%	54.83%	53.50%	49.17%	53.63%
EBITDA Margin	18.10%	19.21%	26.63%	26.88%	25.41%	22.55%	21.22%	28.17%	28.90%	3.78%	28.08%
Operating Margin	15.27%	15.89%	23.18%	23.09%	21.43%	18.09%	15.40%	20.33%	22.35%	-6.04%	16.10%
EBIT Margin	14.09%	15.46%	22.63%	22.78%	21.05%	17.71%	15.66%	22.58%	23.16%	-2.59%	22.19%
Profit (Net Income) Margin	3.82%	34.17%	12.39%	12.13%	22.69%	6.85%	5.75%	9.10%	9.99%	-13.60%	10.00%
Tax Burden Percent	72.50%	525.00%	85.17%	82.98%	173.43%	84.50%	86.14%	63.32%	65.84%	138.51%	68.54%
Interest Burden Percent	37.38%	42.11%	64.31%	64.21%	62.16%	45.74%	42.62%	63.61%	65.50%	379.49%	65.74%
Effective Tax Rate	27.50%	-425.00%	14.83%	17.02%	-73.43%	15.50%	13.86%	36.68%	34.16%	0.00%	31.46%
Return on Invested Capital (ROIC)	9.21%	68.26%	15.96%	15.25%	29.53%	11.74%	9.74%	9.44%	10.57%	-3.07%	7.86%
ROIC Less NNEP Spread (ROIC-NNEP)	7.87%	58.59%	14.51%	13.87%	26.71%	10.09%	8.37%	8.70%	9.63%	-4.84%	7.67%
Return on Net Nonoperating Assets (RNNOA)	-78.19%	-991.10%	-345.10%	-551.91%	-4,514.71%	408.36%	234.73%	161.19%	111.15%	-62.95%	84.17%
Return on Equity (ROE)	-68.98%	-922.84%	-329.14%	-536.66%	-4,485.18%	420.10%	244.48%	170.63%	121.72%	-66.02%	92.02%
Cash Return on Invested Capital (CROIC)	7.60%	16.05%	15.90%	20.23%	17.07%	9.49%	7.12%	3.63%	3.14%	6.79%	11.25%
Operating Return on Assets (OROA)	8.08%	8.41%	12.68%	12.50%	11.35%	9.02%	7.87%	11.06%	11.10%	-1.24%	10.46%
Return on Assets (ROA)	2.19%	18.60%	6.94%	6.66%	12.24%	3.49%	2.89%	4.45%	4.78%	-6.51%	4.71%
Return on Common Equity (ROCE)	-68.98%	-922.84%	-329.14%	-536.66%	-4,485.18%	420.10%	244.48%	170.63%	121.72%	-66.02%	92.02%
Return on Equity Simple (ROE_SIMPLE)	-99.32%	0.00%	2,181.25%	694.44%	263.89%	0.00%	138.38%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	168	1,334	320	308	588	243	201	205	236	-64	161
NOPAT Margin	11.07%	83.45%	19.74%	19.16%	37.16%	15.29%	13.27%	12.87%	14.71%	-4.23%	11.03%
Net Nonoperating Expense Percent (NNEP)	1.34%	9.68%	1.45%	1.38%	2.82%	1.65%	1.37%	0.74%	0.94%	1.78%	0.19%
Return On Investment Capital (ROIC_SIMPLE)	-	15.35%	-	-	-	2.60%	2.11%	2.13%	2.42%	-0.68%	1.70%
Cost of Revenue to Revenue	40.29%	42.74%	41.00%	41.57%	41.66%	43.72%	44.42%	45.17%	46.50%	50.83%	46.37%
SG&A Expenses to Revenue	35.42%	29.35%	26.57%	27.19%	26.68%	29.52%	27.76%	28.42%	25.91%	28.73%	29.04%
R&D to Revenue	9.02%	8.39%	7.83%	8.15%	10.24%	8.17%	6.74%	5.96%	5.24%	6.04%	6.37%
Operating Expenses to Revenue	44.44%	41.36%	35.82%	35.35%	36.92%	38.19%	40.19%	34.50%	31.15%	55.21%	37.53%
Earnings before Interest and Taxes (EBIT)	214	247	367	366	333	282	237	360	371	-39	324
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	275	307	432	432	402	359	321	449	463	57	410
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	97.38	36.46	9.99	7.99	7.09	3.43	3.06	2.47	1.73
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.67	0.54	0.74	0.83	0.77	0.59	0.61	0.40	0.44	0.30	0.25
Price to Earnings (P/E)	7.09	3.33	4.46	5.25	3.79	4.37	5.12	3.59	5.54	9.94	6.34
Dividend Yield	8.63%	8.40%	6.12%	5.49%	5.85%	7.64%	7.52%	8.88%	5.62%	4.75%	1.34%
Earnings Yield	14.11%	30.03%	22.40%	19.05%	26.41%	22.90%	19.53%	27.82%	18.04%	10.06%	15.78%
Enterprise Value to Invested Capital (EV/IC)	1.62	1.43	1.57	1.63	1.52	1.38	1.37	1.20	1.21	1.17	1.08
Enterprise Value to Revenue (EV/Rev)	2.01	1.83	2.02	2.08	2.01	1.87	1.95	1.72	1.74	1.60	1.46
Enterprise Value to EBITDA (EV/EBITDA)	8.69	7.91	8.87	9.23	8.29	7.37	8.09	7.06	6.87	7.70	6.48
Enterprise Value to EBIT (EV/EBIT)	10.34	9.44	10.68	11.20	9.95	8.89	10.06	8.92	8.75	10.69	8.77
Enterprise Value to NOPAT (EV/NOPAT)	11.48	6.01	6.67	7.10	5.86	8.14	8.92	8.69	12.73	27.39	23.82
Enterprise Value to Operating Cash Flow (EV/OCF)	18.51	14.36	16.84	12.38	13.65	12.76	13.06	13.09	11.52	14.19	10.60
Enterprise Value to Free Cash Flow (EV/FCFF)	22.05	9.34	10.27	8.19	9.38	15.14	20.09	34.83	39.67	17.07	9.26
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-14.69	-125.14	181.54	60.11	17.75	18.81	16.52	12.14	9.74	11.49	9.49
Long-Term Debt to Equity	-14.68	-125.01	181.35	60.05	17.73	18.77	16.49	11.98	9.69	11.47	9.47
Financial Leverage	-9.93	-16.92	-23.79	-39.80	-169.02	40.48	28.05	18.53	11.54	13.00	10.98
Leverage Ratio	-12.96	-23.92	-32.88	-56.28	-247.54	62.58	42.45	29.25	18.80	21.22	18.10
Compound Leverage Factor	-4.84	-10.07	-21.14	-36.14	-153.88	28.63	18.09	18.61	12.32	80.51	11.90
Debt to Total Capital	107.30%	100.81%	99.45%	98.36%	94.67%	94.95%	94.29%	92.39%	90.69%	92.00%	90.47%
Short-Term Debt to Total Capital	0.10%	0.10%	0.10%	0.10%	0.11%	0.21%	0.21%	1.19%	0.46%	0.17%	0.17%
Long-Term Debt to Total Capital	107.20%	100.70%	99.35%	98.26%	94.56%	94.74%	94.08%	91.19%	90.23%	91.83%	90.30%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-7.30%	-0.81%	0.55%	1.64%	5.33%	5.05%	5.71%	7.61%	9.31%	8.00%	9.53%
Debt to EBITDA	6.07	6.04	6.03	6.05	5.62	5.46	5.92	5.81	5.55	6.70	6.16
Net Debt to EBITDA	5.78	5.56	5.64	5.56	5.13	5.05	5.55	5.42	5.12	6.26	5.36
Long-Term Debt to EBITDA	6.06	6.03	6.03	6.04	5.61	5.45	5.90	5.74	5.52	6.69	6.15
Debt to NOPAT	8.02	4.58	4.54	4.65	3.97	6.04	6.52	7.15	10.28	23.84	22.65
Net Debt to NOPAT	7.64	4.22	4.24	4.28	3.62	5.58	6.12	6.67	9.50	22.26	19.70
Long-Term Debt to NOPAT	8.01	4.58	4.53	4.65	3.96	6.02	6.50	7.06	10.23	23.80	22.60
Altman Z-Score	1.00	0.97	1.11	1.14	1.12	1.00	0.99	0.95	1.00	0.87	0.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.63	1.54	1.65	1.64	1.70	1.60	1.67	1.65	1.75	1.82	1.97
Quick Ratio	0.83	0.84	0.83	0.84	0.88	0.75	0.77	0.75	0.80	0.80	1.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-349	652	-352	61	-240	-437	-563	-729	-347	155	756
Operating Cash Flow to CapEx	474.55%	502.53%	165.22%	1,037.50%	343.90%	735.85%	234.38%	564.10%	573.91%	313.33%	608.11%
Free Cash Flow to Firm to Interest Expense	-2.60	4.56	-2.69	0.46	-1.91	-2.85	-4.14	-5.56	-2.71	1.42	6.81
Operating Cash Flow to Interest Expense	1.95	2.78	0.58	2.53	1.12	2.55	0.55	1.68	2.06	1.29	2.03
Operating Cash Flow Less CapEx to Interest Expense	1.54	2.22	0.23	2.29	0.79	2.20	0.32	1.38	1.70	0.88	1.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.54	0.56	0.55	0.54	0.51	0.50	0.49	0.48	0.48	0.47
Accounts Receivable Turnover	3.98	3.89	4.24	3.86	3.85	4.13	4.19	4.05	3.98	4.62	4.34
Inventory Turnover	2.36	2.17	2.19	2.13	2.09	2.04	2.05	2.00	1.97	2.13	2.13
Fixed Asset Turnover	6.14	5.69	5.68	5.59	5.57	5.45	5.30	5.17	5.05	5.03	4.98
Accounts Payable Turnover	2.33	2.06	2.68	2.24	2.49	2.18	2.75	2.38	2.62	2.76	2.92
Days Sales Outstanding (DSO)	91.64	93.80	86.03	94.59	94.91	88.41	87.10	90.10	91.79	78.95	84.13
Days Inventory Outstanding (DIO)	154.64	168.20	166.38	171.66	174.29	178.97	177.76	182.10	184.95	171.44	171.64
Days Payable Outstanding (DPO)	156.89	177.49	136.16	162.82	146.47	167.50	132.80	153.47	139.53	132.33	124.83
Cash Conversion Cycle (CCC)	89.39	84.51	116.25	103.42	122.73	99.89	132.07	118.74	137.20	118.05	130.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	7,651	7,997	8,187	8,096	8,479	8,677	8,951	9,030	9,062	8,458	8,356
Invested Capital Turnover	0.83	0.82	0.81	0.80	0.79	0.77	0.73	0.73	0.72	0.73	0.71
Increase / (Decrease) in Invested Capital	517	682	672	247	828	680	764	934	583	-219	-595
Enterprise Value (EV)	12,386	11,474	12,813	13,202	12,911	11,978	12,250	10,813	10,932	9,929	9,012
Market Capitalization	4,146	3,407	4,674	5,250	4,925	3,773	3,841	2,516	2,776	1,859	1,559
Book Value per Share	($2.30)	($0.27)	$0.19	$0.56	$1.91	$1.83	$2.10	$2.82	$3.49	$2.89	$3.47
Tangible Book Value per Share	($22.51)	($20.37)	($20.62)	($20.00)	($18.93)	($21.83)	($21.54)	($20.42)	($19.67)	($17.43)	($16.71)
Total Capital	8,065	8,690	8,762	8,800	9,242	9,352	9,498	9,629	9,734	9,396	9,472
Total Debt	8,654	8,760	8,714	8,656	8,749	8,880	8,956	8,896	8,828	8,644	8,569
Total Long-Term Debt	8,646	8,751	8,705	8,647	8,739	8,860	8,936	8,781	8,783	8,628	8,553
Net Debt	8,240	8,067	8,139	7,952	7,986	8,205	8,409	8,297	8,156	8,070	7,453
Capital Expenditures (CapEx)	55	79	46	32	41	53	32	39	46	45	37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,153	906	1,085	1,059	1,213	975	1,229	1,338	1,394	1,404	1,332
Debt-free Net Working Capital (DFNWC)	1,567	1,599	1,660	1,763	1,976	1,650	1,776	1,937	2,066	1,978	2,448
Net Working Capital (NWC)	1,559	1,590	1,651	1,754	1,966	1,630	1,756	1,822	2,021	1,962	2,432
Net Nonoperating Expense (NNE)	110	788	119	113	229	134	114	60	76	141	15
Net Nonoperating Obligations (NNO)	8,240	8,067	8,139	7,952	7,986	8,205	8,409	8,297	8,156	7,706	7,453
Total Depreciation and Amortization (D&A)	61	60	65	66	69	77	84	89	92	96	86
Debt-free, Cash-free Net Working Capital to Revenue	18.75%	14.47%	17.09%	16.69%	18.93%	15.23%	19.53%	21.30%	22.12%	22.59%	21.61%
Debt-free Net Working Capital to Revenue	25.48%	25.53%	26.15%	27.78%	30.83%	25.77%	28.22%	30.84%	32.79%	31.82%	39.72%
Net Working Capital to Revenue	25.35%	25.39%	26.01%	27.64%	30.68%	25.46%	27.90%	29.01%	32.07%	31.56%	39.46%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.23	$2.13	$0.78	$0.76	$1.39	$0.43	$0.34	$0.56	$0.61	($0.79)	$0.56
Adjusted Weighted Average Basic Shares Outstanding	255.59M	255.24M	255.70M	257.29M	257.50M	257.05M	257.86M	259.94M	259.98M	259.50M	260.37M
Adjusted Diluted Earnings per Share	$0.23	$2.12	$0.78	$0.75	$1.38	$0.42	$0.33	$0.56	$0.61	($0.78)	$0.55
Adjusted Weighted Average Diluted Shares Outstanding	256.35M	256.27M	258.36M	258.60M	259.76M	259.15M	261.00M	260.16M	260.65M	260.76M	262.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	255.61M	255.64M	257.17M	257.47M	257.54M	257.95M	259.96M	259.97M	259.98M	260.32M	262.60M
Normalized Net Operating Profit after Tax (NOPAT)	168	218	340	308	237	250	275	206	236	-59	182
Normalized NOPAT Margin	11.07%	13.67%	20.95%	19.16%	15.00%	15.71%	18.16%	12.95%	14.71%	-3.90%	12.49%
Pre Tax Income Margin	5.27%	6.51%	14.55%	14.62%	13.08%	8.10%	6.68%	14.37%	15.17%	-9.82%	14.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.60	1.73	2.80	2.79	2.64	1.84	1.74	2.75	2.90	-0.36	2.92
NOPAT to Interest Expense	1.26	9.33	2.44	2.35	4.67	1.59	1.48	1.57	1.84	-0.58	1.45
EBIT Less CapEx to Interest Expense	1.19	1.17	2.45	2.55	2.32	1.50	1.51	2.45	2.54	-0.77	2.59
NOPAT Less CapEx to Interest Expense	0.84	8.77	2.09	2.11	4.34	1.24	1.24	1.27	1.48	-1.00	1.12
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	50.26%	28.74%	27.79%	29.60%	22.75%	34.38%	39.73%	32.71%	31.54%	47.06%	8.94%
Augmented Payout Ratio	50.26%	28.74%	27.79%	29.60%	22.75%	34.38%	39.73%	32.71%	31.54%	47.06%	8.94%

Financials Breakdown Chart

Key Financial Trends

Here are key takeaways from Organon & Co. (NASDAQ: OGN) based on the last four years of quarterly statements, focusing on trends in revenue, profitability, cash flow, and the balance sheet. The analysis emphasizes 2025 quarterly results to highlight recent performance and evolving risk/strengths for retail investors.

Positive operating cash flow in every 2025 quarter: Net cash from continuing operating activities was 75.0M (Q1), 220.0M (Q2), 264.0M (Q3), and 141.0M (Q4), all in positive territory.
Consistent free cash flow in 2025: Free cash flow (cash from operations minus capital expenditures) per quarter was approximately 43.0M (Q1), 181.0M (Q2), 218.0M (Q3), and 96.0M (Q4); full-year FCF around 538M across four quarters.
Stable, shareholder-friendly dividends: Cash dividends per share remained at 0.28 USD across Q1–Q4 2025, indicating a steady return to shareholders.
Solid gross margins in 2025 (roughly mid-50% range): Gross margin was roughly 55.6% (Q1), 54.8% (Q2), 53.5% (Q3), and 49.2% (Q4) as gross profit divided by revenue, signaling healthy core product profitability despite variability in quarterly costs.
Revenue largely ranged around 1.5–1.6B per quarter in 2025, with modest quarter-to-quarter fluctuations but no sustained uptrend or collapse.
Equity base shown steady growth through 2025 (approx. 0.54B in Q1 to ~0.90B by Q3), suggesting improving capitalization, though the company still carries substantial liabilities.
Balance-sheet composition includes high goodwill and intangible assets (~4.6B combined in recent quarters), which introduces impairment risk but is typical of growth-oriented moves and large acquisitions.
Near-term profitability weakness in Q4 2025: Net income attributable to common shareholders was -205.0M in Q4 2025, following positive earnings in the preceding quarters of the year.
Very high debt load: Long-term debt hovered around 8.7B in 2025, with total liabilities near 12.6B–12.9B, reflecting substantial leverage and ongoing debt-servicing obligations.
Financing activity remained a net cash outflow contributor in recent quarters: Net cash from financing activities was -187.0M (Q4 2025), -76.0M (Q3 2025), -223.0M (Q2 2025), and -75.0M (Q1 2025), indicating ongoing use of cash for debt repayments and distributions.

05/14/26 12:16 PM ETAI Generated. May Contain Errors.

Organon & Co. Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Organon & Co.'s fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Organon & Co.'s net income appears to be on a downward trend, with a most recent value of $187 million in 2025, falling from $3.22 billion in 2019. The previous period was $864 million in 2024. Check out Organon & Co.'s forecast to explore projected trends and price targets.

Organon & Co.'s total operating income in 2025 was $824 million, based on the following breakdown:

Total Gross Profit: $3.31 billion
Total Operating Expenses: $2.49 billion

Over the last 6 years, Organon & Co.'s total revenue changed from $7.78 billion in 2019 to $6.22 billion in 2025, a change of -20.1%.

Organon & Co.'s total liabilities were at $12.12 billion at the end of 2025, a 4.1% decrease from 2024, and a 162.1% increase since 2020.

In the past 5 years, Organon & Co.'s cash and equivalents has ranged from $12 million in 2020 to $737 million in 2021, and is currently $574 million as of their latest financial filing in 2025.

Over the last 6 years, Organon & Co.'s book value per share changed from 0.00 in 2019 to 2.89 in 2025, a change of 289.3%.

Related Companies

Financial statements for NYSE:OGN last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Financials

Financials Breakdown Chart

Key Financial Trends

Organon & Co. Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Financials

Annual Income Statements for Organon & Co.

Quarterly Income Statements for Organon & Co.

Annual Cash Flow Statements for Organon & Co.

Quarterly Cash Flow Statements for Organon & Co.

Annual Balance Sheets for Organon & Co.

Quarterly Balance Sheets for Organon & Co.

Annual Metrics And Ratios for Organon & Co.

Quarterly Metrics And Ratios for Organon & Co.

Financials Breakdown Chart

Key Financial Trends

Organon & Co. Financials - Frequently Asked Questions

When does Organon & Co.'s financial year end?

How has Organon & Co.'s net income changed over the last 6 years?

What is Organon & Co.'s operating income?

How has Organon & Co.'s revenue changed over the last 6 years?

How much debt does Organon & Co. have?

How much cash does Organon & Co. have?

How has Organon & Co.'s book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools